Skip to main content
Premium Trial:

Request an Annual Quote

Jackson Lab, Shriners Hospitals to Study Genetics of Pediatric Orthopedic Disorders

NEW YORK — The Jackson Laboratory and the Shriners Hospitals for Children said on Thursday that they have partnered to investigate the genetic causes of orthopedic disorders in pediatric patients.

Under the terms of the deal, Shriners Hospitals will perform next-generation sequencing on DNA samples from families at its 22 hospitals and outpatient locations in North America and from its international network of outreach clinics. Participants will include children with orthopedic conditions such as clubfoot, scoliosis, and osteogenesis imperfecta.

Jackson Lab investigators will analyze the data and develop mouse models with the same genetic variations as patients participating in the research program. The partners expect the work to advance the discovery of new treatments.

The deal with the Jackson Lab comes a few months after Shriners Hospitals established a new genomics institute in Tampa, Florida with Genome Medical.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.